title: Successful implementation of a P&T-approved therapeutic interchange program of angiotensin II receptor blockers in a medical center in Taiwan.
abstract: OBJECTIVE
  Therapeutic interchange is not a common practice in the medical society in Asia. We used clinic blood pressure readings, patients' tolerance, and cost saving as measures to evaluate the impact of a therapeutic interchange program implemented at a medical center in Taiwan.
  
  
  METHODS
  Taipei Medical University-Wan Fang Hospital initiated a therapeutic interchange program involving angiotensin II receptor blockers (ARBs). Data were retrospectively collected for 444 outpatients who were converted from other ARBs to candesartan. Evaluation of therapeutic efficacy, adverse effects associated with therapy, and drug costs was conducted before and after the program implementation.
  
  
  RESULTS
  Patients whose treatment was converted to candesartan experienced no statistically significant differences in blood pressure, and the average number of antihypertensive agents used per patient remained unchanged. A direct cost savings of US$62,237 was estimated for the 444 patients studied. Only 3.15% of the patients developed adverse drug reactions potentially related to candesartan, and none required hospitalization.
  
  
  CONCLUSIONS
  Based on the results of this retrospective chart review, the present ARB therapeutic interchange program was successfully developed and implemented. This is the first study to establish the positive impact of a well-run ARB therapeutic interchange program in Taiwan.
authors.affiliation: Department of Pharmacy, Taipei Medical University-Wan Fang Hospital, Taipei, Taiwan.
authors.forename: Yen-Ying
authors.initials: YY
authors.lastname: Lee
authors.forename: Paul
authors.initials: P
authors.lastname: Hsiao
authors.forename: You-Meei
authors.initials: YM
authors.lastname: Lin
authors.forename: Yu-Hsuan
authors.initials: YH
authors.lastname: Yen
authors.forename: Hsiang-Yin
authors.initials: HY
authors.lastname: Chen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D047228:Angiotensin II Type 1 Receptor Blockers / Q000191:economics / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000191:economics / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D001794:Blood Pressure; D017046:Cost Savings; D057915:Drug Substitution; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008297:Male; D008875:Middle Aged; D010606:Pharmacy and Therapeutics Committee; D012189:Retrospective Studies; D013624:Taiwan; D013777:Tetrazoles / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D057911:Angiotensin Receptor Antagonists; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan